2'-Fucosyllactose exposure was associated with improvement in patient-reported disease control, gut microbiota modulation, and cross-compartmental host-microbial metabolic profile modifications in mild-to-moderate ulcerative colitis.
2'-FL significantly increased Bifidobacterium abundance in patients with mild-to-moderate ulcerative colitis.
2'-FL was associated with improved patient-reported disease control despite no clear treatment effect on conventional clinical indices.
2'-FL exposure was associated with fecal metabolite profile changes consistent with altered microbial carbohydrate metabolism.
Exploratory analyses suggested that age and baseline microbiota composition may influence clinical and biological responsiveness to 2'-FL.
The study design was a randomized, double-blind, placebo-controlled crossover trial in patients with mild-to-moderate UC.
This research suggests that a specific sugar found in human breast milk, called 2'-fucosyllactose (2'-FL), can meaningfully alter the gut bacteria and metabolic activity in adults with mild-to-moderate ulcerative colitis (UC), an inflammatory bowel disease. In a carefully designed clinical trial with 38 UC patients, those who took 2'-FL supplements for 28 days showed a significant increase in beneficial Bifidobacterium bacteria in their gut compared to those who took a placebo. This is notable because the gut microbiome in people with active UC is known to differ from that of healthy individuals, and Bifidobacterium are generally considered beneficial bacteria. Although standard clinical measures of disease activity did not show a statistically significant improvement, patients themselves reported better disease control while taking 2'-FL. Changes in metabolites detected in stool samples were consistent with shifts in how gut bacteria process carbohydrates, suggesting the supplement was biologically active beyond just changing bacterial counts. The researchers also found preliminary evidence that a patient's age and the composition of their gut bacteria before starting the supplement may influence how much benefit they receive, which could help identify who might respond best to this type of treatment. This research suggests that human milk oligosaccharides like 2'-FL, which are well-studied in infant nutrition, may also have meaningful effects in adults with inflammatory bowel conditions. The findings point to microbiome modulation as a potential pathway through which 2'-FL might support gut health in UC, though larger studies would be needed to confirm clinical benefits and determine which patients are most likely to benefit.
Upload your bloodwork. We'll cross-reference your results against this study and 4,700 others.
Upload Your LabsKennedy J, De Silva A, Morales P, Poveda Turrado C, Walton G, Gibson G. (2026). 2'-Fucosyllactose modulates gut microbiota and systemic metabolism in mild-to-moderate ulcerative colitis: a randomized crossover trial.. Journal of Crohn's & colitis. https://doi.org/10.1093/ecco-jcc/jjag120